Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.2.825

PDCD4 as a Predictor of Sensitivity to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients  

Dou, Xue (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Wang, Ren-Ben (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Meng, Xiang-Jiao (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Yan, Hong-Jiang (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Jiang, Shu-Mei (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Zhu, Kun-Li (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Xu, Xiao-Qing (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Chen, Dong (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Song, Xian-Rang (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Academy of Medical Sciences, University of Jinan)
Mu, Dian-Bin (Department of Pathology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.2, 2014 , pp. 825-830 More about this Journal
Abstract
Objective: The purpose of this study was to examine the role of programmed cell death 4 (PDCD4) expression in predicting tumor response to neoadjuvant chemoradiotherapy and outcomes for patients with locally advanced rectal cancer. Methods: Clinicopathological factors and expression of PDCD4 were evaluated in 92 patients with LARC treated with nCRT. After the completion of therapy, 4 cases achieved clinical complete response (cCR), and thus the remaining 88 patients underwent a standardized total mesorectal excision procedure. There were 38 patients (41.3%) with a good response (TRG 3-4) and 54 (58.7%) with a poor one (TRG 0-2). Results: Immunohistochemical staining analyses showed that patients with high expression of PDCD4 were more sensitive to nCRT than those with low PDCD4 expression (P=0.02). High PDCD4 expression before nCRT and good response (TRG3-4) were significantly associated with improved 5-year disease-free survival and 5-year overall survival (P<0.05). Multivariate analysis demonstrated that the pretreatment PDCD4 expression was an independent prognostic factor. Conclusion: Our study demonstrated that high expression of PDCD4 protein is a useful predictive factor for good tumor response to nCRT and good outcomes in patients with LARC.
Keywords
Rectal cancer; programmed cell death 4; neoadjuvant chemoradiotherapy; sensitivity; tumor regression;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Horiuchi A, Iinuma H, Akahane T, Shimada R, Watanabe T (2012). Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients. Oncol Rep, 27, 1384-92.
2 Horsman MR, Bohm L, Margison GP, et al (2006). Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys, 64, 551-61.   DOI
3 Kheirelseid EA, Miller N, Chang KH, Nugent M, Kerin MJ (2013). Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol, 4, 144-57.
4 Kim IJ, Lim SB, Kang HC, et al (2007). Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum, 50, 1342-53.   DOI   ScienceOn
5 Lim SC, Hong R (2011). Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage. Oncol Lett, 2, 1053-7.
6 Bitomsky N, Wethkamp N, Marikkannu R, Klempnauer KH (2008). siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression. Oncogene, 27, 4820-9.   DOI
7 Chang KH, Miller N, Kheirelseid EA, et al (2011). MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol, 37, 597-603.   DOI   ScienceOn
8 Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH (2004). Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene, 23, 8135-45.   DOI
9 Anastasov N, Hofig I, Vasconcellos IG, et al (2012). Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol, 7, 206.   DOI
10 Bosset JF, Collette L, Calais G, et al (2006). Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 355, 1114-23.   DOI   ScienceOn
11 Chen Y, Liu W, Chao T, et al (2008). MicroRNA-21 downregulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett, 272, 197-205.   DOI
12 Wang WQ, Zhang H, Wang HB, et al (2010). Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/ Akt signaling pathway. Mol Diagn Ther, 14, 155-61.   DOI   ScienceOn
13 Suarez J, Vera R, Balen E, et al (2008). Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis, 10, 563-8.   DOI   ScienceOn
14 Supiot S, Gouraud W, Campion L, et al (2013). Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study. World J Gastroenterol, 19, 3249-54.   DOI
15 Zhang X, Wang X, Song X, et al (2010). Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci, 101, 2163-70.   DOI
16 Vecchio FM, Valentini V, Minsky BD, et al (2005). The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys, 62, 752-60.   DOI   ScienceOn
17 Woodard J, Sassano A, Hay N, Platanias LC (2008). Statindependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res, 14, 4640-9.   DOI
18 Zhang H, Ozaki I, Mizuta T, et al (2006). Involvement of programmed cell death 4 in transforming growth factorbeta1- induced apoptosis in human hepatocellular carcinoma. Oncogene, 25, 6101-12.   DOI
19 Zhang Z, Dubois R (2001). Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene, 20, 4450-6.   DOI
20 Rodel C, Martus P, Papadoupolos T, et al (2005). Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol, 23, 8688-96.   DOI   ScienceOn
21 Mudduluru G, Medved F, Grobholz R, et al (2007). Loss of programmed cell death 4 expression marks adenomacarcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer, 110, 1697-707.   DOI
22 Onishi Y, Kizaki H (1996). Molecular cloning of the genes suppressed in RVC lympuhoma cells by topoisomerase inhibitors. Biochem Biophys Res Commun, 228, 7-13.   DOI
23 Schlichter U, Burk O, Worpenberg S, Klempnauer KH (2001). The chicken Pdcd4 gene is regulated by v-Myb. Oncogene, 20, 231-9.   DOI
24 Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM (2005). Pekarsky: Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res, 65, 11282-6.   DOI   ScienceOn
25 Sanghera P, Wong DW, Mcconkey CC, Geh JI, Hartley A (2008). Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol), 20, 176-83.   DOI
26 Sauer R, Becker H, Hohenberger W, et al (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351,1731-40.   DOI   ScienceOn
27 Shibahara K, Asano M, Ishida Y, et al (1995). Isolation of a novel mouse gene MA- 3 that is induced upon programmed cell death. Gene, 166, 297-301.   DOI
28 Gerard JP, Conroy T, Bonnetain F, et al (2006). Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 24, 4620-5.   DOI   ScienceOn
29 Cmarik JL, Min H, Hegamyer G, et al (1999). Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic trans-formation. Proc Natl Acad Sci USA, 96, 14037-42.   DOI
30 Dorrello NV, Peschiaroli A, Guardavaccaro D, et al (2006). S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science, 314, 467-71.   DOI
31 Dworak O, Keilholz L, Hoffmann A (1997). Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 12, 19-23.   DOI   ScienceOn
32 Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX (2013). MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technolog Med Sci, 33, 525-9.   DOI
33 Soejima H, Miyoshi O, Yoshinagaga H, et al (1999). Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet, 87, 113-4.   DOI